We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Two-Minute COVID-19 Test Uses Nanosensor Technology to Detect Presence of SARS-CoV-2 Infection in Blood at POC

By LabMedica International staff writers
Posted on 16 Jul 2021
Print article
Image: Two-Minute COVID-19 Test Uses Nanosensor Technology to Detect Presence of SARS-CoV-2 Infection in Blood at POC (Photo courtesy of NanoDx, Inc.)
Image: Two-Minute COVID-19 Test Uses Nanosensor Technology to Detect Presence of SARS-CoV-2 Infection in Blood at POC (Photo courtesy of NanoDx, Inc.)
A SARS-CoV-2 testing system addresses existing diagnostic challenges by providing a rapid assessment from a nasal, throat, saliva, or finger stick of blood sample in a two minute test.

The simple, low-cost system that includes a portable handheld, analyzer, disposable cartridges and secure software for seamless systems integration has been developed by NanoDx, Inc. (Boston, MA, USA). NanoDx is licensing IBM Research’s (Yorktown Heights, NY, USA) nanoscale sensor technology for use in its diagnostic platform. IBM’s technology was developed with the goal of advancing sensor metal-oxide semi-conductive (CMOS) technology.

NanoDx plans to use this sensor technology for diagnostic platforms designed to provide rapid, accurate and inexpensive detection of different diseases. NanoDx also plans to use this technology to advance efforts to diagnose a variety of medical conditions rapidly and accurately, including COVID-19, different forms of influenza, traumatic brain injury (TBI), sepsis and stroke in the field of in vitro diagnostics, as well as biosensors. The IBM-designed nano biosensors are CMOS-compatible, which means they may be more cost-effectively and rapidly manufactured in high-volume. When integrated with automation circuitry, these tiny sensors may enable NanoDx’s real-time, point-of-care diagnostics technology to detect and quantify biomarkers from small fluid specimens in less than two minutes.

NanoDx is commercializing its real-time, point-of-care diagnostics platform and has built an extensive intellectual property portfolio around its nanosensor design and manufacturing processes that encompasses the entire field of in vitro diagnostics. The NanoDx System for SARS-CoV-2 is pursuing FDA Emergency Use Authorization to expand rapid COVID-19 testing.

"The field of diagnostics has changed rapidly during the past year with the emergence of COVID-19," said Sharad Joshi, President and Chief Executive Officer of NanoDx. "This global pandemic has further highlighted the need for a convenient, fast and accurate diagnostic so proper treatments can be delivered to patients as quickly as possible with the goal of shortening recovery times. As we move forward, our access to IBM's technology in the in vitro diagnostics and biosensor fields will enable us to pursue developing a high throughput diagnostics platform at a significantly lower cost."

"Our work with NanoDx is another example of IBM's collaborative approach to what we call 'hard tech': solving the deep technical problems that affect our everyday lives," said Mukesh Khare, Vice President, Hybrid Cloud Research at IBM Research. "Notably, this CMOS-compatible device can be manufactured in an existing foundry, providing easily scalable and cost-effective hardware. The integration of this technology design with NanoDx's highly-advanced nanosensor platform can help accelerate the ability to bring an extensive array of diagnostic solutions to market."

Related Links:
NanoDx, Inc.
IBM Research


New
Gold Supplier
Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit
Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Prepacked)
New
Liquid Handling & Assay Processing System
Nexar
New
SARS-CoV-2 RT-PCR Module
NEBNext ARTIC SARS-CoV-2 RT-PCR Module
New
POCT Analyzer
HTY-100 Plus POCT Analyzer

Print article

Channels

Molecular Diagnostics

view channel
Image: Primary angle closure glaucoma can cause permanent blindness if not treated quickly. A highly sensitive genetic test has been developed (Photo courtesy of Flinders University)

Highly Sensitive Genetic Test for Glaucoma Developed

In open-angle glaucoma, the angle in the eye where the iris meets the cornea is as wide and open as it should be, but the eye’s drainage canals become clogged over time, causing an increase in internal... Read more

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.